Rafael Holdings Inc represents values of integrity, innovation, and excellence in its corporate philosophy. As a leading company in its field, Rafael Holdings Inc focuses on delivering superior products and services to its customers. With a strong commitment to ethical business practices and customer satisfaction, the company aims to create long-term value for its stakeholders. By continuously pushing the boundaries of technology and embracing a culture of collaboration, Rafael Holdings Inc strives to shape the future of its industry. By aligning these values with its corporate mission, Rafael Holdings Inc remains dedicated to providing top-tier solutions and fostering growth and success for both the company and its clients.

Rafael Holdings Inc is primarily present in the United States.

Rafael Holdings Inc has achieved several significant milestones. In recent years, the company has successfully expanded its real estate portfolio, acquiring strategically located properties in key markets. Additionally, Rafael Holdings has established partnerships and collaborations with leading companies in the biotechnology and pharmaceutical industries, leveraging its expertise and resources to drive innovation and growth. The company has also made notable advancements in healthcare, particularly in the fields of oncology and rare diseases, by investing in cutting-edge research and development. These milestones highlight Rafael Holdings Inc's commitment to innovation, strategic partnerships, and promoting advancements in the healthcare industry.

Rafael Holdings Inc is a company with a rich history and background. Established in 2018, Rafael Holdings Inc is a pharmaceutical company based in Newark, New Jersey. It was founded as a subsidiary of IDT Corporation, a multinational holding company. Rafael Holdings Inc focuses on the development and commercialization of novel therapies for the treatment of cancer and other serious diseases. With a dedication to innovation and research, the company aims to make a significant impact in the healthcare industry. As a promising player in the pharmaceutical sector, Rafael Holdings Inc continually strives to improve patient outcomes and bring about advancements in medical science.

The main competitors of Rafael Holdings Inc in the market include companies such as Johnson & Johnson, Pfizer, and Merck & Co. These well-established pharmaceutical companies compete with Rafael Holdings Inc in various aspects of the industry, including research, development, and commercialization of innovative drugs and therapies. As Rafael Holdings Inc aims to make a mark in the pharmaceutical sector, it faces tough competition from these leaders in the market.

Rafael Holdings Inc is primarily active in the biotechnology and real estate industries.

Rafael Holdings Inc is a diversified holding company focused on acquiring and managing technology and real estate assets. Its business model revolves around identifying potential investment opportunities in these sectors and strategically managing their growth and profitability. By actively participating in the governance and management of its subsidiaries, Rafael Holdings Inc aims to maximize long-term value for its shareholders. The company leverages its expertise and resources to establish innovative businesses and unlock the potential of its portfolio companies. Through its targeted approach, Rafael Holdings Inc aims to generate sustainable revenue streams and create value for its stakeholders.

Pašreizējais KGV Rafael Holdings nevar tikt aprēķināts.

KUV šobrīd Rafael Holdings nevar aprēķināt.

AlleAktien kvalitātes vērtējums Rafael Holdings ir 2/10.

Pašreiz nevar aprēķināt apgrozījumu Rafael Holdings.

Pašlaik peļņa Rafael Holdings nevar tikt aprēķināta.

Rafael Holdings Inc is an innovative investment company specializing in investing in rapidly growing and transformative technology companies. The company's business model is based on strategically diversifying its investments in various areas to secure a broad range of business and growth opportunities. The company aims to invest in companies operating in two specific sectors: life sciences and technology. Within these two sectors, various areas are covered, including biotechnology, medical devices, artificial intelligence, and cybersecurity. In the life sciences sector, Rafael Holdings focuses on the development and commercialization of diagnostic and therapeutic solutions for a variety of diseases and disease areas. The company has a stake in a significant number of leading biotechnology companies and has also initiated innovative projects in collaboration with other leading institutions, such as the development of drugs for diseases like cancer, Parkinson's, and Alzheimer's. In addition, Rafael Holdings has also invested in technology companies that offer solutions for IT management and artificial intelligence. These companies can be involved in areas such as cybersecurity, data management, or big data analytics. Including its investments in life sciences and technology companies, Rafael Holdings also has its own subsidiary called Edgemont Pharmaceuticals, LLC. Edgemont Pharmaceuticals develops and markets innovative and cost-effective drugs for unmet medical needs, particularly for patients who have no specific treatment alternatives. Rafael Holdings is also known for its involvement in various non-profit initiatives and foundations. One of these is the Leukemia & Lymphoma Society, for which Rafael Holdings is a significant partner in funding cancer research projects. Rafael Holdings' growth strategy is based on diversifying its investments in the two sectors, exploring new business opportunities in these sectors, and seeking new technological solutions and innovations that have the potential to enhance the business. Overall, Rafael Holdings offers a wide range of business opportunities covered by its investments in various companies in the life sciences and technology sectors. Although the company is primarily active in the investment field, they also have a subsidiary that develops their own products. The company's business model is based on a sophisticated portfolio strategy, enabling a wide diversification of the portfolio.

Rafael Holdings izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Rafael Holdings vai uzņēmums nedod dividendes.

Rafael Holdings ISIN ir US75062E1064.

Rafael Holdings WKN ir A2JDMF.

Rafael Holdings simbols ir RFL.

Pēdējo 12 mēnešu laikā Rafael Holdings maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Rafael Holdings plāno maksāt dividendes 0 USD apmērā.

Rafael Holdings pašreizējā dividendu rentabilitāte ir .

Rafael Holdings maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Rafael Holdings pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Rafael Holdings tiek piešķirts nozarei "Nekustamais īpašums".

Lai saņemtu pēdējo dividendu Rafael Holdings apmērā 0 USD, kas tika izmaksāta 7.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 7.09.2024..

Pēdējās dividendes izmaksa notika 7.09.2024..

Gadā 2023, Rafael Holdings izmaksāja 0 USD dividendes.

Rafael Holdings dividendes tiek izmaksātas USD.